795 trials (keyword fallback)
Malignant Melanoma
Primary: Diagnostic Accuracy to Detect Melanoma — 20; 92; 1; 140 number of skin lesions
Melanoma (Skin)
Primary: Sun Protection Habits Index — 2.9; 3 scores on a scale
Melanoma
Primary: Overall Response Rate to Treatment of Melanoma With Disulfiram and Chelated Zinc — 0 participants
Melanoma
Primary: Number of Participants With T-cell Response to Peptide Vaccine — 6; 1; 12; 19 Participants
Melanoma
Primary: Immunologic Response Rate — 7; 1; 0; 0 Participants
High-Risk Melanoma
Primary: Immunologic Response Rate — 2; 0; 0; 3 Participants
Melanoma
Primary: Influence of a Patient's Melanoma Diagnosis on the Survivor's and Broader Family's Skin Cancer Prevention Activity. — 24; 22; 2; 5 Participants
Melanoma · Unresectable (Stage III) Melanoma · Metastatic (Stage IV) Melanoma
Primary: Measure of Efficacy of the Phase 2 Dose of RTA 408 in Combination With Nivolumab Using Overall Response Rate (ORR; Complete Plus Partial Responses) According to RECIST…
Melanoma · Skin Cancer · Cancer
Primary: Overall Objective Response (Complete Response or Partial Response) — 2; 2; 15 participants
Advanced Melanoma · Triple-Negative Breast Cancer
Primary: The Primary Efficacy Endpoint Was ORR, Defined as the Proportion of Subjects Demonstrating CR or PR Based on RECIST v1.1 Criteria. — 1; 1; 0; 5 Participants
Melanoma
Primary: Number of Participants Who Completed SSE at Specified Time Points — 217; 242; 475; 238 Participants — p=<0.001
Melanoma
Primary: Determine Sensitivity of Blood-Based Assay
Brain Neoplasms
Primary: Establish a Safe Dose for Oral 5-ALA Administration — 0; 0; 0; 0 Dose Limiting Toxicity
Recurrent Melanoma · Stage IIIB Skin Melanoma · Stage IIIC Skin Melanoma
Primary: Objective Tumor Response (Complete Response and Partial Response) and Progression in Participants With Stage III or IV Melanoma Following Treatment With Temsirolimus and…
Melanoma (Skin)
Primary: Progression-free Survival at 6 Months — 32.8; 56.1 % of patients alive and progression free